FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter Revenue and Cash Balance Preliminary total company revenue is estimated to be $19.7 million in the fourth quarter of 2023, an increase of 18% compared with $16.7 million in the fourth quarter of 2022 Preliminary revenue from pharma tests, enterprise ...

Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - Chief Medical Officer and EVP, Research and Development Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Mark Massaro - VTIG Swayampakula Ramakanth - H.C. Wainwright Operator Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call. All participants ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (State or other jurisdiction of incorporation or organization) Delaware 27-5411038 (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 00 ...

Personalis, Inc. (NASDAQ:PSNL) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Caroline Corner - Investor Relations Chris Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial Officer and Chief Operating Officer Rich Chen - Chief Medical Officer and Executive Vice President, Research & Development Conference Call Participants Tejas Savant - Morgan Stanley Mark Massaro - BTIG Swayampakula Ramakanth - H.C. Wainwright Dan Brennan - Cowen Mike Matson - Ne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Personalis, Inc. (NASDAQ:PSNL) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Caroline Corner – Investor Relations Chris Hall – Chief Executive Officer and President Aaron Tachibana – Chief Financial Officer and Chief Operating Officer Rich Chen – Chief Medical Officer and Executive Vice President-R&D Conference Call Participants Mike Matson – Needham & Co. Sean Lee – H.C. Wainwright Operator Greetings ladies and gentlemen. And welcome to Personalis’ First Quarter 2023 Earnings ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

Personalis, Inc. (NASDAQ:PSNL) Q4 2022 Results Conference Call February 23, 2023 5:00 PM ET Company Participants Caroline Corner - Investor Relations Aaron Tachibana - Interim Chief Financial Officer and Chief Financial Officer Chris Hall - President Rich Chen - Chief Medical Officer, and SVP of R&D Conference Call Participants Joseph Flanagan - Cowen Vivian Bais - BTIG Arthur He - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Personalis Fourth Quarter 2022 Earnings Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission File Number 001-38943 Personalis, Inc. (Exact name of Registrant as specified in its Charter) Delaware 27-5411038 (State or other jurisdiction ...

Financial Data and Key Metrics Changes - Total company revenue for Q3 2022 was $14.9 million, a decrease of 33% compared to the same period last year, primarily due to a $13.7 million decline in VA MVP revenue [29] - Oncology business revenue increased by 73% year-over-year, driven mainly by volume increases from Natera, which accounted for half of the oncology revenue in the quarter [29] - Gross margin was 16.7% for Q3 2022, down from 36.2% in the same period last year, primarily due to under absorbed overhead costs from decreased VA MVP revenue and increased expenses to support growing oncology revenue [30] - Net loss for Q3 was $26.5 million, compared to a net loss of $17.7 million for the same period last year, with a net loss per share of $0.58 [33] Business Line Data and Key Metrics Changes - All revenue in Q3 2022 came from the oncology business, which saw a significant increase in revenue [29] - The company recognized approximately $1.5 million from an exome-scale liquid biopsy project for a leading global pharmaceutical company [23] Market Data and Key Metrics Changes - The company has seen growing interest in its NeXT Personal platform from pharmaceutical companies in the U.S., Europe, and China, with two pharma placing orders over $1 million each [19] - The Veterans Administration Million Veterans Program (VA MVP) has begun to enroll veterans again, with a goal of reaching 1 million enrollees in 2023 [24] Company Strategy and Development Direction - The centerpiece of the company's oncology business is the NeXT Personal MRD test, which aims to provide highly sensitive and informative cancer monitoring [6] - The company plans to launch its MRD test as a lab-developed test (LDT) in 2023 and has been building a commercial team to support this initiative [20] - The company is focused on personalized diagnostics, integrating tumor characterization capabilities into its MRD test to provide actionable insights for oncologists [12] Management's Comments on Operating Environment and Future Outlook - Management noted a slowdown in biopharma demand due to budget concerns and macroeconomic conditions, particularly affecting smaller biotechs [40] - The company anticipates that the current challenging environment may continue into early 2023, but remains optimistic about the long-term need for cancer solutions [40] - Management expects gross margins to improve in the long term as oncology revenue scales up [31] Other Important Information - The company has a strong balance sheet with cash and short-term investments of $192.8 million, providing more than two years of cash runway [34] - The company has initiated a brand evolution to align with its strategy of creating highly personalized cancer diagnostic tests [22] Q&A Session Summary Question: Concerns about tightening budgets among large pharma customers - Management acknowledged a slowdown in biopharma demand due to budget concerns, particularly affecting smaller biotechs, and anticipates this trend may continue into early 2023 [40] Question: Impact of staffing shortages on sample shipments - Management confirmed that sample shipments are slower due to staffing shortages affecting patient enrollments and sample collections [44] Question: Implications of FDA requests for additional clinical data on MRD efforts - Management believes their test's performance and data from extensive collaborations will position them favorably compared to competitors facing similar FDA scrutiny [46] Question: Timing and strategy for refreshing sequencing infrastructure - Management indicated that new sequencing technologies could significantly reduce costs, with expectations for improvements in gross margins beginning in early 2024 [50] Question: Revenue expectations from the new Shanghai facility - Management does not anticipate revenue from the Shanghai facility in 2022, with expectations for moderate revenue in 2023 [59] Question: Factors driving gross margin changes - Management attributed the decline in gross margin primarily to decreased VA MVP volume, with expectations for recovery as the program resumes [68] Question: Cash burn expectations for 2023 - Management expects operating cash burn to be below $85 million in 2023, with significant expenditures related to the new facility accounted for in 2022 [78]